Advertisement

The Relationship of Diabetic Retinopathy and Glaucoma

  • David J. Browning
  • Michael H. Rotberg
Chapter

Abstract

Diabetes, diabetic retinopathy, and their various treatments can each influence a patient’s risk of developing not only neovascular glaucoma, but open angle, narrow angle, and secondary glaucoma as well. After reviewing the connections between these types of glaucoma and diabetes, the pathogenesis and management of neovascular glaucoma will be discussed in detail.

Keywords

Vascular Endothelial Growth Factor Diabetic Retinopathy Proliferative Diabetic Retinopathy Central Retinal Vein Occlusion Intravitreal Bevacizumab 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262–267.PubMedCrossRefGoogle Scholar
  2. 2.
    Wild S, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–1053.PubMedCrossRefGoogle Scholar
  3. 3.
    Bonovas S, Peponis V, Filioussi K. Diabetes mellitus as a risk factor for primary open-angle glaucoma: a meta-analysis. Diabetes Med. 2004;21:609–614.CrossRefGoogle Scholar
  4. 4.
    Chopra V, Varma R, Francis BA et al. Type 2 diabetes mellitus and the risk of open-angle glaucoma. The Los Angeles Latino Eye Study. Ophthalmology. 2008;115:227–232.PubMedCrossRefGoogle Scholar
  5. 5.
    Memarzadeh F, Ying-Lai M, Azen SP, Varma R, on behalf of the Los Angeles Latino Eye Study Group. Associations with intraocular pressure in Latinos: the Los Angeles Latino Eye Study. Am J Ophthalmol. 2008;146:69–76.PubMedCrossRefGoogle Scholar
  6. 6.
    Nakamura M, Kanamori A, Negi A. Diabetes mellitus as a risk factor for glaucomatous optic neuropathy. Ophthalmologica. 2005;219:1–10.PubMedCrossRefGoogle Scholar
  7. 7.
    Krueger RR, Ramos-Esteban JC. How might corneal elasticity help us understand diabetes and intraocular pressure? J Refract Surg. 2007;23:85–88.PubMedGoogle Scholar
  8. 8.
    The Advanced Glaucoma Intervention Study (AGIS):12. Baseline risk factors for sustained loss of visual field and visual acuity in patients with advanced glaucoma. Am J Ophthalmol. 2002;134:499–512.Google Scholar
  9. 9.
    Armstrong JR, Daily RK, Dobson HL, Girard LJ. The incidence of glaucoma in diabetes mellitus. A comparison with the incidence of glaucoma in the general population. Am J Ophthalmol. 1960;50:55–63.PubMedGoogle Scholar
  10. 10.
    Becker B. Diabetes mellitus and primary open-angle glaucoma. The XXVII Edward Jackson Memorial Lecture. Am J Ophthalmol. 1971;1:1–16.Google Scholar
  11. 11.
    De Voogd S, Ikram MK, Wolfs RC, et al. Is diabetes mellitus a risk factor for open-angle glaucoma? The Rotterdam Study. Ophthalmology. 2006;113:1827–1831.PubMedCrossRefGoogle Scholar
  12. 12.
    Klein BE, Klein R, Jensen SC. Open-angle glaucoma and older-onset diabetes. The Beaver Dam Eye Study. Ophthalmology. 1994;101:1173–1177.PubMedGoogle Scholar
  13. 13.
    Klein BE, Klein R, Moss SE. Intraocular pressure in diabetic persons. Ophthalmology. 1984;91:1356–1360.PubMedGoogle Scholar
  14. 14.
    Klein BE, Klein R, Moss SE. Incidence of self reported glaucoma in people with diabetes mellitus. Br J Ophthalmol. 1997;81:743–747.PubMedCrossRefGoogle Scholar
  15. 15.
    Mitchell P, Smith W, Chey T, et al. Open-angle glaucoma and diabetes: the Blue Mountains Eye Study. Australia. Ophthalmology. 1997;104:712–718.PubMedGoogle Scholar
  16. 16.
    Nielsen NV. The prevalence of glaucoma and ocular hypertension in type 1 and 2 diabetes mellitus. An epidemiological study of diabetes mellitus on the island of Falster, Denmark. Acta Ophthalmol. 1983;61:662–672.Google Scholar
  17. 17.
    Leske MC. The epidemiology of open-angle glaucoma: a review. Am J Epidemiol. 1983;118:166–191.PubMedGoogle Scholar
  18. 18.
    Wu SY, Leske MC. Associations with intraocular pressure in the Barbados Eye Study. Arch Ophthalmol. 1997;115:1572–1576.PubMedGoogle Scholar
  19. 19.
    Bonomi L, Marchini G, Marraffa M, Bernardi P, Morbio R, Varotto A. Vascular risk factors for primary open-angle glaucoma: the Egna–Neumarkt Study. Ophthalmology. 2000;107:1287–1293.PubMedCrossRefGoogle Scholar
  20. 20.
    Hennis A, Wu SY, Nemesure B, Leske MC. Hypertension, diabetes, and longitudinal changes in intraocular pressure. Ophthalmology. 2003;110:908–914.PubMedCrossRefGoogle Scholar
  21. 21.
    Dielemans I, de Jong PT, Stolk R, Vingerling JR, Grobbee DE, Hofman A. Primary open-angle glaucoma, intraocular pressure, and diabetes mellitus in the general elderly population: the Rotterdam Study. Ophthalmology. 1996;103:1271–1275.PubMedGoogle Scholar
  22. 22.
    Bankes JL. Ocular tension and diabetes mellitus. Br J Ophthalmol. 1967;51:557–561.PubMedCrossRefGoogle Scholar
  23. 23.
    Grødum K, Heijl A, Bengtsson B. Optic disc hemorrhages and generalized vascular disease. J Glaucoma. 2002;11:226–230.PubMedCrossRefGoogle Scholar
  24. 24.
    Kahn HA, Leibowitz HM, Ganley JP, et al. The Framingham Eye Study. II. Association of ophthalmic pathology with single variables previously measured in the Framingham Heart Study. Am J Epidemiol. 1977;106:33–41.PubMedGoogle Scholar
  25. 25.
    Leibowitz HM, Krueger DE, Maunder LR, et al. The Framingham Eye Study monograph: an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973–1975. Surv Ophthalmol. 1980;24:335–610.PubMedCrossRefGoogle Scholar
  26. 26.
    Leske MC, Connell AM, Wu SY, et al. Risk factors for open angle glaucoma. The Barbados Eye Study. Arch Ophthalmol. 1995;113:918–924.PubMedGoogle Scholar
  27. 27.
    Tielsch JM, Katz J, Quigley HA, et al. Diabetes, intraocular pressure, and primary open-angle glaucoma in the Baltimore Eye Survey. Ophthalmology. 1995;102:48–53.PubMedGoogle Scholar
  28. 28.
    Wilson MR, Hertzmark E, Walker AM, et al. A case–control study of risk factors in open angle glaucoma. Arch Ophthalmol. 1987;105:1066–1071.PubMedGoogle Scholar
  29. 29.
    Ellis JD, Morris AD, MacEwen CJ. Should diabetic patients be screened for glaucoma? DARTS/MEMO Collaboration. Br J Ophthalmol. 1999;83:369–372.PubMedCrossRefGoogle Scholar
  30. 30.
    Pache M and Flammer J. A sick eye in a sick body? Systemic findings in patients with primary open-angle glaucoma. Surv Ophthalmol. 2006;51:179–212.CrossRefGoogle Scholar
  31. 31.
    Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK, Wilson MR, Kass MA, for the Ocular Hypertension Treatment Study Group. The ocular hypertension treatment study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:714–720.PubMedGoogle Scholar
  32. 32.
    Blake DR, Nathan DM. Acute angle closure glaucoma following rapid correction of hyperglycemia. Diabetes Care. 2003;26:3197–3198.PubMedCrossRefGoogle Scholar
  33. 33.
    Sorokanich S, Wand M, Nix HR. Angle closure glaucoma and acute hyperglycemia. Arch Ophthalmol. 1986;104:1434.PubMedGoogle Scholar
  34. 34.
    Smith JP. Angle closure glaucoma and acute hyperglycemia (Letter). Arch Ophthalmol. 1987;105:454–455.PubMedGoogle Scholar
  35. 35.
    Clark CV. Diabetes mellitus in primary glaucomas. Ann Acad Med Singapore. 1989;18:190–194.PubMedGoogle Scholar
  36. 36.
    Saw SM, Wong TY, Ting S, Foong AW, Foster PJ. The relationship between anterior chamber depth and the presence of diabetes in the Tanjong Pagar Survey. Am J Ophthalmol. 2007;144:325–326.PubMedCrossRefGoogle Scholar
  37. 37.
    Wiemer NGM, Dubbelman M, Kostense PJ, Ringens PF, Polak BCP. The influence of diabetes mellitus type 1 and 2 on the thickness, shape, and equivalent refractive index of the human crystalline lens. Ophthalmology. 2008;115:1679–1686.PubMedCrossRefGoogle Scholar
  38. 38.
    Wiemer NGM, Dubbelman M, Hermans EA, Ringens PF, Polak BCP. Changes in the internal structure of the human crystalline lens with diabetes mellitus type 1 and type 2. Ophthalmology. 2008;115:2017–2023.PubMedCrossRefGoogle Scholar
  39. 39.
    Jones R, Rhee DJ. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol. 2006;17:163–167.PubMedGoogle Scholar
  40. 40.
    Jermak CM, Dellacroce JT, Heffez J, Peyman GA. Triamcinolone acetonide in ocular therapeutics. Surv Ophthalmol. 2007;52:503–522.PubMedCrossRefGoogle Scholar
  41. 41.
    Kramar M, Vu L, Whitson JT, He YG. The effect of intravitreal triamcinolone on intraocular pressure. Curr Med Res Opin. 2007;23:1253–1258.PubMedCrossRefGoogle Scholar
  42. 42.
    Batioglu F, Ozmert E, Parmak N, Celik S. Two year results of intravitreal triamcinolone acetonide injection for the treatment of diabetic macular edema. Int Ophthalmol. 2007;27:299–306.PubMedCrossRefGoogle Scholar
  43. 43.
    Vasconcelos-Santos DV, Nehemy PG, Schachat AP, Nehemy MB. Secondary ocular hypertension after intravitreal injection of 4 mg of triamcinolone acetonide: incidence and risk factors. Retina. 2008;28:573–580.PubMedCrossRefGoogle Scholar
  44. 44.
    Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: two year results of a double masked, placebo controlled, randomized clinical trial. Ophthalmology. 2006;113:1533–1538.PubMedCrossRefGoogle Scholar
  45. 45.
    Lau LI, Chen KC, Lee FL, Chen SJ, Ko YC, Liu CJL, Hsu WM. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection in a Chinese population. Am J Ophthalmol. 2008;146:573–578.PubMedCrossRefGoogle Scholar
  46. 46.
    Cunningham MA, Edelman JF, Kaushal S. Intravitreal steroids for macular edema: the past, the present, and the future. Surv Ophthalmol. 2008;53:139–149.PubMedCrossRefGoogle Scholar
  47. 47.
    Callanan DG, Jaffe GJ, Martin DF, Pearson PA, Comstock TL. Treatment of posterior uveitis with a fluocinolone acetonide implant. Arch Ophthalmol. 2008;126:1191–1201.PubMedCrossRefGoogle Scholar
  48. 48.
    Ricci F, Missiroli F, Parravano M. Argon laser trabeculoplasty in triamcinolone acetonide induced ocular hypertension refractory to maximal medical treatment. Eur J Ophthalmol. 2006;16:756–757.PubMedGoogle Scholar
  49. 49.
    Viola F, Morescalchi F, Staurenghi G. Argon laser trabeculoplasty for intractable glaucoma following intravitreal triamcinolone. Arch Ophthalmol. 2006;124:133–134.PubMedCrossRefGoogle Scholar
  50. 50.
    Rubin B, Taglienti A, Rothman RF, Marcus CH, Serle JB. The effect of selective laser trabeculoplasty on intraocular pressure in patients with intravitreal steroid-induced elevated intraocular pressure. J Glaucoma. 2008;17:287–292.PubMedCrossRefGoogle Scholar
  51. 51.
    Realini T. Selective laser trabeculoplasty: a review. J Glaucoma. 2008;17:497–502.PubMedCrossRefGoogle Scholar
  52. 52.
    Robin AL, Sjaarda R, Suan EP. A novel long-lasting therapy for glaucoma caused by intravitreal triamcinolone acetonide: anterior juxtascleral depot of anecortave acetate. Presented at Annual Meeting of the American Glaucoma Society, Charleston, SC, March 2006.Google Scholar
  53. 53.
    Robin AL, et al. Anterior juxtascleral delivery of anecortave acetate in eyes with primary open angle glaucoma: a pilot investigation. Am J Ophthalmol. 2009;147:45–50.PubMedCrossRefGoogle Scholar
  54. 54.
    Katz GJ, et al. A study of anecortave acetate (7.5 and 15 mg) vs vehicle in patients with open angle glaucoma. Presented at American Academy of Ophthalmology meeting, November 2008.Google Scholar
  55. 55.
    Eid TM, Radwan A, el-Manawy W, el-Hawary I. Outcome of intravitreal bevacizumab (Avastin) followed by aqueous shunting tube surgery for management of intractable neovascular glaucoma. Poster at American Academy of Ophthalmology November 2008.Google Scholar
  56. 56.
    Kuang TM, Liu CJ, Chou CK, Hsu WM. Clinical experience in the management of neovascular glaucoma. J Chin Med Assoc. 2004;67:131–135.PubMedGoogle Scholar
  57. 57.
    Nabili S, Kirkness CM. Trans-scleral diode laser cyclophoto-coagulation in the treatment of diabetic neovascular glaucoma. Eye. 2004;18:352–256.Google Scholar
  58. 58.
    Sothornwit N. Intravitreal bevacizumab for Ahmed glaucoma valve implantation in neovascular glaucoma: a case report. J Med Assoc Thai. 2008;91(Suppl 1):S162–S165.Google Scholar
  59. 59.
    Wand M, Dueker DK, Aiello LM, Grant WM. Effects of panretinal photocoagulation on rubeosis iridis, angle neovascularization, and neovascular glaucoma. Am J Ophthalmol. 1978;86:332–339.PubMedGoogle Scholar
  60. 60.
    Ringvold A, Davanger M. Iris neovascularization in eyes with pseudoexfoliation syndrome. Br J Ophthalmol. 1981;65:138–141.PubMedCrossRefGoogle Scholar
  61. 61.
    Shimizu K, Kobayashi K, Muraoka K. Midperipheral fundus involvement in diabetic retinopathy. Ophthalmology. 1981;88:601–612.PubMedGoogle Scholar
  62. 62.
    Hamanaka T, Akabane N, Yajima T, et al. Retinal ischemia and angle neovascularization in proliferative diabetic retinopathy. Am J Ophthalmol. 2001;132:648–658.PubMedCrossRefGoogle Scholar
  63. 63.
    Terasaki H, Miyake Y, Mori M, et al. Fluorescein angiography of extreme peripheral retina and rubeosis iridis in proliferative diabetic retinopathy. Retina. 1999;19:302–308.PubMedCrossRefGoogle Scholar
  64. 64.
    Steel DHW, Habib MS, Park S, et al. Entry site neovascularization and vitreous cavity hemorrhage after diabetic vitrectomy the predictive value of inner sclerostomy site ultrasonography. Ophthalmology. 2008;115:525–532.PubMedCrossRefGoogle Scholar
  65. 65.
    Tolentino MJ, McLeod DS, Taomoto M, et al. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol. 2002;133:373–385.PubMedCrossRefGoogle Scholar
  66. 66.
    Meyer-Schwickerath R, Pfeiffer A, Blum WF, et al. Vitreous levels of the insulin-like growth factors I and III, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic patients. J Clin Invest. 1993;92:2620–2625.PubMedCrossRefGoogle Scholar
  67. 67.
    John T, Sassani JW, Eagle RC. The myofibroblastic component of rubeosis iridis. Ophthalmology. 1983;90:721–728.PubMedGoogle Scholar
  68. 68.
    Rice TA, Michels RG, Maguire MG, Rice EF. The effect of lensectomy on the incidence of iris neovascularization and neovascular glaucoma after vitrectomy for diabetic retinopathy. Am J Ophthalmol. 1983;95:1–11.PubMedGoogle Scholar
  69. 69.
    Tolentino MJ, Miller JW, Gragoudis ES, et al. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol. 1996;114:964–970.PubMedGoogle Scholar
  70. 70.
    Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol. 1996;114:66–71.PubMedGoogle Scholar
  71. 71.
    Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (avastin) treatment. Retina, J Retin Vitreous Dis. 2006;26:352–356.Google Scholar
  72. 72.
    Davidorf FH, Mouser JG, Derick RJ. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina. 2006;26:354–356.PubMedCrossRefGoogle Scholar
  73. 73.
    Tripathi RC, Li J, Tripathi BJ, et al. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology. 1998;105:232–237.PubMedCrossRefGoogle Scholar
  74. 74.
    Gartner S, Henkind P. Neovascularization of the iris (rubeosis iridis). Surv Ophthalmol. 1978;22:291–312.PubMedCrossRefGoogle Scholar
  75. 75.
    Anderson DM, Morin JD, Hunter WS. Rubeosis iridis. Can J Ophthalmol. 1971;6:183–188.PubMedGoogle Scholar
  76. 76.
    Schulze RR. Rubeosis iridis. Am J Ophthalmol. 1967;63:487–495.PubMedGoogle Scholar
  77. 77.
    Weiter J, Zuckerman R. The influence of the photoreceptor–RPE complex on the inner retina. Ophthalmology. 1980;87:1133–1139.PubMedGoogle Scholar
  78. 78.
    Aiello LP, Arrigg PG, Keyt BA, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. New Eng J Med. 1994;331:1480–1487.PubMedCrossRefGoogle Scholar
  79. 79.
    Ohrt V. Rubeosis iridis diabetica. Acta Ophthalmol. 1958;36:556–558.Google Scholar
  80. 80.
    Ohnishi Y, Ishibashi T, Sagawa T. Fluorescein gonioangiography in diabetic neovascularization. Graefe's Arch Clin Exp Ophthalmol. 1994;232:199–204.CrossRefGoogle Scholar
  81. 81.
    Helbig H, Kellner U, Bornfeld N, Foerster MH. Rubeosis iridis after vitrectomy for diabetic retinopathy. Graefe's Arch Clin Exp Ophthalmol. 1998;236:730–733.CrossRefGoogle Scholar
  82. 82.
    Michels R. Vitrectomy for complications of diabetic retinopathy. Arch Ophthalmol. 1978;96:237–246.PubMedGoogle Scholar
  83. 83.
    Bandello F, Brancato R, Lattanzio R, et al. Relation between iridopathy and retinopathy in diabetes. Br J Ophthalmol. 1994;78:542–545.PubMedCrossRefGoogle Scholar
  84. 84.
    Tasman W, Magargal LE, Augsburger JJ. Effects of argon laser photocoagulation on rubeosis iridis and angle neovascularization. Ophthalmology. 1980;87:400–402.PubMedGoogle Scholar
  85. 85.
    Diabetic Retinopathy Study Research Group. Diabetic retinopathy study, report number 6: design, methods, and baseline results. Invest Ophthalmol Vis Sci. 1981;21:149–209.Google Scholar
  86. 86.
    Ohrt V. The frequency of rubeosis iridis in diabetic patients. Ophthalmologica. 1971;49:301–307.Google Scholar
  87. 87.
    Murphy RP, Egbert PR. Regression of iris neovascularization following panretinal photocoagulation. Arch Ophthalmol. 1979;97:700–702.PubMedGoogle Scholar
  88. 88.
    Teich SA, Walsh JB. A grading system for iris neovascularization-prognostic implications for treatment. Ophthalmology. 1981;88:1102–1106.PubMedGoogle Scholar
  89. 89.
    Aiello LM, Wand M, Liang G. Neovascular glaucoma and vitreous hemorrhage following cataract surgery in patients with diabetes mellitus. Ophthalmology. 1983;90:814–820.PubMedGoogle Scholar
  90. 90.
    Browning DJ. Risk of missing angle neovascularization by omitting screening gonioscopy in patients with diabetes mellitus. Am J Ophthalmol. 1991;112:212.PubMedGoogle Scholar
  91. 91.
    Browning DJ, Scott AQ, Peterson CB, et al. The risk of missing angle neovascularization by omitting screening gonioscopy in acute central retinal vein occlusion. Ophthalmology. 1998;105:776–784.PubMedCrossRefGoogle Scholar
  92. 92.
    Pe'er J, Neufeld M, Baras M, et al. Rubeosis in retinoblastoma – histologic findings and the possible role of vascular endothelial growth factor in its induction. Ophthalmology. 1997;104:1251–1258.PubMedGoogle Scholar
  93. 93.
    Henkind P. Ocular neovascularization. The Krill Memorial Lecture. Am J Ophthalmol. 1978;85:287–301.PubMedGoogle Scholar
  94. 94.
    Ehrenberg M, McCuen BW, Schindler RH, Machemer R. Rubeosis iridis: preoperative iris fluorescein angiography and periocular steroids. Ophthalmology. 1984;91:321–325.PubMedGoogle Scholar
  95. 95.
    Scuderi JJ, Blumenkranz MS, Blankenship G. Regression of diabetic rubeosis iridis following successful surgical reattachment of the retina by vitrectomy. Retina. 1982;2:193–196.PubMedCrossRefGoogle Scholar
  96. 96.
    Tolentino FI, Cajita VN, Gancayco T, Skates S. Vitreous hemorrhage after closed vitrectomy for proliferative diabetic retinopathy. Ophthalmology. 1989;96:1495–1500.PubMedGoogle Scholar
  97. 97.
    Lewis H, Abrams GW, Williams GA. Anterior hyaloidal fibrovascular proliferation after diabetic vitrectomy. Am J Ophthalmol. 1987;104:607–613.PubMedGoogle Scholar
  98. 98.
    Lewis H, Abrams GW, Foos RY. Clinicopathologic findings in anterior hyaloidal fibrovascular proliferation after diabetic vitrectomy. Am J Ophthalmol. 1987;104:614–618.PubMedGoogle Scholar
  99. 99.
    Hanley JA, Lippman-Hand A. If nothing goes wrong, is everything alright? JAMA. 1983;259:1743–1745.CrossRefGoogle Scholar
  100. 100.
    Eypasch E, Lefering R, Kum CK. Probability of adverse events that have not yet occurred: a statistical reminder. BMJ. 1995;311:619–620.PubMedGoogle Scholar
  101. 101.
    Blinder KJ, Friedman SM, Mames RN. Diabetic iris neovascularization. Am J Ophthalmol. 1998;120:393–395.Google Scholar
  102. 102.
    Brancato R, Bandello F, Lattanzio R. Iris fluorescein angiography in clinical practice. Surv Ophthalmol. 1997;42:41–70.PubMedCrossRefGoogle Scholar
  103. 103.
    Mandelbaum S, Chew EY, Christman LM, et al. Comprehensive adult medical eye evaluation. 2008. American Academy of Ophthalmology.Google Scholar
  104. 104.
    Coleman SL, Green WR, Patz A. Vascular tufts of the pupillary margin of the iris. Am J Ophthalmol. 1977;83:881–883.PubMedGoogle Scholar
  105. 105.
    Dahlmann AH, Benson MT. Spontaneous hyphema secondary to iris vascular tufts. Arch Ophthalmol. 2001;119:1728.PubMedGoogle Scholar
  106. 106.
    Davies N. Letter. Eye. 2001;15:688–691.PubMedGoogle Scholar
  107. 107.
    Bandello F, Brancato R, Lattanzio R, et al. Biomicroscopy versus fluorescein angiography of the iris in the detection of diabetic iridopathy. Graefes Arch Clin Exp Ophthalmol. 1993;231:444–448.PubMedCrossRefGoogle Scholar
  108. 108.
    Sanborn GE, Symes DJ, Magaragal LE. Fundus-iris fluorescein angiography: evaluation of its use in the diagnosis of rubeosis iridis. Ann Ophthalmol. 1986;18:52–58.PubMedGoogle Scholar
  109. 109.
    Jensen VA, Lundbaek K. Fluorescence angiography of the iris in recent and long-term diabetics. Acta Ophthalmol. 1968;46:584–585.Google Scholar
  110. 110.
    Kottow MH. Iris neovascular tufts. Arch Ophthalmol. 1980;98:2084.PubMedGoogle Scholar
  111. 111.
    Vannas A. Fluorescein angiography of the vessels of the iris. Acta Ophthalmol. 1969;105:1–75.Google Scholar
  112. 112.
    Parodi MB, Bondel E, Russo D, Ravalico G. Iris indocyanine green video angiography in diabetic iridopathy. Br J Ophthalmol. 1996;80:416–419.PubMedCrossRefGoogle Scholar
  113. 113.
    Tauber J, Lahav M, Erzurum SA. New clinical classification for iris neovascularization. Ophthalmology. 1987;94:542–544.PubMedGoogle Scholar
  114. 114.
    Nomura T, Furukawa H, Kurinoto S. Development and classification of neovascular glaucoma in diabetic eye disease: histopathological study. Acta Ophthalmol Soc Jpn. 1976;86:166–175.Google Scholar
  115. 115.
    Kubota T, Tawara A, Hata T, et al. Neovascular tissue in the intertrabecular spaces in eyes with neovascular glaucoma. Br J Ophthalmol. 1996;80:750–754.PubMedCrossRefGoogle Scholar
  116. 116.
    Weiss DI, Gold D. Neofibrovascularization of iris and anterior chamber angle: a clinical classification. Ann Ophthalmol. 1978;10:488–491.PubMedGoogle Scholar
  117. 117.
    Little HL, Rosenthal AR, Dellaporta A, Jacobson DR. The effect of panretinal photocoagulation on rubeosis iridis and neovascular glaucoma. Am J Ophthalmol. 1976;81:804–809.PubMedGoogle Scholar
  118. 118.
    Beasley H. Rubeosis iridis in aphakic diabetics. JAMA. 1970;213:128.PubMedCrossRefGoogle Scholar
  119. 119.
    Schiff WM, Barile GR, Hwang JC et al. Diabetic vitrectomy: influence of lens status upon anatomic and visual outcomes. Ophthalmology. 2007;114:544–550.PubMedCrossRefGoogle Scholar
  120. 120.
    Yang CM, Yeh PT, Yang CH. Intravitreal long-acting gas in the prevention of early postoperative vitreous hemorrhage in diabetic vitrectomy. Ophthalmology. 2007;114:710–715.PubMedCrossRefGoogle Scholar
  121. 121.
    Yeh PT, Yang CM, Yang CH, Huang JS. Cryotherapy of the anterior retina and sclerotomy sites in diabetic vitrectomy to prevent recurrent vitreous hemorrhage. Ophthalmology. 2005;112:2095–2102.PubMedCrossRefGoogle Scholar
  122. 122.
    Azzolini C, Brancato R, Camesasca FI, August 1993 (Vol.100 I8PP). Influence of silicone oil on iris microangiopathy in diabetic vitrectomized eyes. Ophthalmology. 1993;100:1152–1158.Google Scholar
  123. 123.
    Laatikainen L. Preliminary report on effect of retinal panphotocoagulation on rubeosis iridis and neovascular glaucoma. Br J Ophthalmol. 1977;61:278–284.Google Scholar
  124. 124.
    Vernon SA, Cheng H. Panretinal cryotherapy in neovascular disease. Br J Ophthalmol. 1988;72:401–405.PubMedCrossRefGoogle Scholar
  125. 125.
    Pauleikhoff D, Gerke E. Photocoagulation in diabetic rubeosis iridis and neovascular glaucoma. Klin Monatsbl Augenheil. 1987;190:11–16.CrossRefGoogle Scholar
  126. 126.
    Striga M, Ivanisevic M. Comparison between efficacy of full- and mild-scatter (panretinal) photocoagulation on the course of diabetic rubeosis iridis. Ophthalmologica. 1993;207:144–147.PubMedCrossRefGoogle Scholar
  127. 127.
    Parodi MB, Iacono P. Photodynamic therapy with verteporfin for anterior segment neovascularizations in neovascular glaucoma. Am J Ophthalmol. 2004;138:157–158.PubMedCrossRefGoogle Scholar
  128. 128.
    Spiteri Cornish K, Ramamurthi S, Saidkasimova S, Ramaesh K. Intravitreal bevacizumab and augmented trabeculectomy for neovascular glaucoma in young diabetic patients. Eye. 2008;23:979–981.PubMedCrossRefGoogle Scholar
  129. 129.
    Avery RL, Pearlman J, Pieramici DJ et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113:1695–1705.PubMedCrossRefGoogle Scholar
  130. 130.
    Grover S, Gupta SK, Sharma RK, Brar VS, Chalam KV. Intracameral bevacizumab effectively reduces aqueous VEGF levels in neovascular glaucoma. Br J Ophthalmol. 2009;93:1273–1274.CrossRefGoogle Scholar
  131. 131.
    Chalam KV, Gupta SK, Grover S, Brar VS, Agarwal S. Intracameral Avastin dramatically resolves iris neovascularization and reverses neovascular glaucoma. Eur J Ophthalmol. 2008;18:255–262.PubMedGoogle Scholar
  132. 132.
    Grisanti S, Biester S, Peters S, Tatar O, Ziemssen F, Bartz-Schmidt KU, Tuebingen Bevacizumab Study Group. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol. 2006;142:158–160.PubMedCrossRefGoogle Scholar
  133. 133.
    Miki A, Oshima Y, Otori Y, et al. Efficacy of intravitreal bevacizumab as adjunctive treatment with pars plana vitrectomy, endolaser photocoagulation, and trabeculectomy for neovascular glaucoma. Br J Ophthalmol. 2008;92:1431–1433.PubMedCrossRefGoogle Scholar
  134. 134.
    May DR, Bergstrom TJ, Parmet AJ, Schwartz JG. Treatment of neovascular glaucoma with transscleral panretinal cryotherapy. Ophthalmology. 1980;87:1106–1111.PubMedGoogle Scholar
  135. 135.
    Flaxel CJ, Larkin GB, Broadway DB, et al. Peripheral transscleral retinal diode laser for rubeosis iridis. Retina. 1997;17:421–429.PubMedGoogle Scholar
  136. 136.
    Hilton GF. Panretinal cryotherapy for diabetic rubeosis. Arch Ophthalmol. 1979;97:776.PubMedGoogle Scholar
  137. 137.
    Allen RC, Bellows AR, Hutchinson BT, Murphy SD. Filtration surgery in the treatment of neovascular glaucoma. Ophthalmology. 1982;89:1181–1187.PubMedGoogle Scholar
  138. 138.
    Skuta GL, Parrish RK II. Wound healing in glaucoma filtering surgery. Surv Ophthalmol. 1987;32:149–170.PubMedCrossRefGoogle Scholar
  139. 139.
    Miller JW, StinsonWG, Folkman J. Regression of experimental iris neovascularization with systemic alpha-interferon. Ophthalmology. 2008;100:9–14.Google Scholar
  140. 140.
    Genaidy M, Kazi A, Peyman G, et al. Effect of squalamine on iris neovascularization in monkeys. Retina. 2002;22:772–778.PubMedCrossRefGoogle Scholar
  141. 141.
    Sir Duke-Elder S., Jay B. eds. Haemorrhagic glaucoma. In: System of Ophthalmology. Vol. 9. London: Henry Kimpton;1969:667.Google Scholar
  142. 142.
    Sivak-Callcott JS, O’Day DM, Gass JDM, Tsai JC. Evidence based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology. 2001;108:1767–1778.PubMedCrossRefGoogle Scholar
  143. 143.
    Ehlers JP, Shah CP, Fenton GL, Hoskins EN, Shelsta HN. The Wills Eye Manual: office and Emergency Room Diagnosis and Treatment of Eye Disease. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2008:214–217.Google Scholar
  144. 144.
    Silva Paula J, Jorge R, Alves Costa R, Rodrigues Mde L, Scott IU. Short-term results of intravitreal bevacizumab (Avastin) on anterior segment neovascularization in neovascular glaucoma. Acta Ophthalmol Scand. 2006;84:556–557.PubMedCrossRefGoogle Scholar
  145. 145.
    Oshima Y, Sakgauchi H, Gomi F, Tano Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2006;142:155–158.PubMedCrossRefGoogle Scholar
  146. 146.
    Beutel J, Peters S, Luke M, Aisenbrey S, Szurman P, Spitzer MS, Yoeruek E, The Bevacizumab Study Group, Grisanti S. Bevacizumab as adjuvant for neovascular glaucoma. Acta Ophthalmol. Sept 20, 2008 (E-pub).Google Scholar
  147. 147.
    Jiang Y, Liang X, Li X, Tao Y, Wang K. Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of iris neovascularization caused by proliferative diabetic retinopathy. Acta Ophthalmol. 2008 Sep 18 (E-pub)Google Scholar
  148. 148.
    Ehlers JP, Spirn MJ, Lam A, Sivalingam A, Samuel MA, Tasman W. Combination intravitreal bevacizumab/panretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma. Retina. 2008;28:696–702.PubMedCrossRefGoogle Scholar
  149. 149.
    Gheith ME, Siam GA, de Barros DS, Garg SJ, Moster MR. Role of intravitreal bevacizumab in neovascular glaucoma. J Ocul Pharmacol Ther. 2007;23:487–491.PubMedCrossRefGoogle Scholar
  150. 150.
    Iliev ME, Domig D, Wolf-Schnurrbursch U, Wolf S, Sarra G-M. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol. 2006;142:1054–1056.PubMedCrossRefGoogle Scholar
  151. 151.
    Chilov MN, Grigg JR, Playfair TJ. Bevacizumab (Avastin) for the treatment of neovascular glaucoma. Clin Exp Ophthalmol. 2007;35:494–496.CrossRefGoogle Scholar
  152. 152.
    Wakabayashi T, Oshima Y, Sakaguchi H, Ikuno Y, Miki A, Gomi F, Otori Y, Kamei M, Kusada S, Tano Y. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology. 2008;115:1571–1580.PubMedCrossRefGoogle Scholar
  153. 153.
    Martinez-Carpio PA, Bonafonte-Marquez E, Heredia-Garcia CD, Bonafonte-Rovo S. Efficacy and safety of intravitreal injection of bevacizumab in the treatment of neovascular glaucoma: systemic review. Arch Soc Esp Oftalmol. 2008;83:579–588.PubMedCrossRefGoogle Scholar
  154. 154.
    Yoeruek E, Spitzer MS, Tatar O, Aisenbrey S, Bartz-Schmidt KU, Szurman P. Safety profile of bevacizumab on cultured human corneal cells. Cornea. 2007;26:977–982.PubMedCrossRefGoogle Scholar
  155. 155.
    Sharma, RK, Chalam, KV, et al. Evaluation of cytotoxic effects of bevacizumab on human corneal endothelial cells. Cornea. 2009;28:328–333.PubMedCrossRefGoogle Scholar
  156. 156.
    Netland PA. The Management of Neovascular Glaucoma in 2008. Presentation at the annual meeting of the American Academy of Ophthalmology, Atlanta, GA. November 10, 2008.Google Scholar
  157. 157.
    Al Obeidan SA, Osman EA, Al-Amro SA, Kangave D, Abu El-Asrar AM. Full preoperative panretinal photocoagulation improves the outcome of trabeculectomy with mitomycin C for neovascular glaucoma. Eur J Ophthalmol. 2008;18:758–764.PubMedGoogle Scholar
  158. 158.
    Kitnarong N, Chindasub P, Metheetrairut A. Surgical outcome of intravitreal bevacizumab and filtration surgery in neovascular glaucoma. Adv Ther. 2008;25:438–443.PubMedCrossRefGoogle Scholar
  159. 159.
    Pappas GD, Panagiotoglou T, Kounali VD, Koukoulasis MG, Fanouriakis CD. Intracameral bevacizumab and augmented trabeculectomy with mitomycin C for the treatment of neovascular glaucoma. Poster at American Academy of Ophthalmology November 2008.Google Scholar
  160. 160.
    Grewal DS, Jain R, Kumar H, Grewal SPS. Evaluation of subconjunctival bevacizumab as an adjunct to trabeculectomy. Ophthalmology. 2008;115:2141–2145.PubMedCrossRefGoogle Scholar
  161. 161.
    Welsandt GR, Mietz H, Becker M, et al. Effect of bevacizumab on 3T3 fibroblasts in vitro: possible role in wound healing modulation. Invest Ophthalmol Vis Sci 48:E-abstract 836, 2007.Google Scholar
  162. 162.
    Icchpujani P, Ramasubramanian A, Kaushik S, Pandav SS. Bevacizumab in glaucoma: a review; Can J Ophthalmol. 2007;42:812–815.CrossRefGoogle Scholar
  163. 163.
    Kapetansky F, et al. Subconjunctival injection(s) of bevacizumab for failing filtering blebs. Poster at American Academy of Ophthalmology November 2008.Google Scholar
  164. 164.
    Wang J, Harasymowycz PJ. Subconjunctival bevacizumab injection for glaucoma filtering surgery: a case series. Poster at American Academy of Ophthalmology November 2008.Google Scholar
  165. 165.
    Yalvac IS, Eksioglu U, Satana B, Duman S. Long term results of Ahmed glaucoma valve and Molteno implant in neovascular glaucoma. Eye. 2007;21:65–70.PubMedCrossRefGoogle Scholar
  166. 166.
    Lloyd MA, Sedlak T, Heuer DK, et al. Clinical experience with the single-plate Molteno implant in complicated glaucomas. Ophthalmology. 1992;99:679–687.PubMedGoogle Scholar
  167. 167.
    Every SG, Molteno AC, Bevin TH, Herbison P. Long term results of Molteno implant insertion in cases of neovascular glaucoma. Arch Ophthalmol. 2006;124:355–360.PubMedCrossRefGoogle Scholar
  168. 168.
    Luttrul JK, Avery RL. Pars plana implant and vitrectomy for treatment of neovascular glaucoma. Retina. 1995;15:379–387.CrossRefGoogle Scholar
  169. 169.
    Faghihi H, Hajizadeh F, Hahammadi SF, Kadkhoda A, Peyman GA, Riazi-Esfahani M. Pars plana Ahmed valve implant and vitrectomy in the management of neovascular glaucoma. Opthalmic Surg Lasers Imaging. 2007;38:292–300.Google Scholar
  170. 170.
    Smith MF, Doyle JW, Fanous MM. Modified aqueous drainage implants in the treatment of complicated glaucomas in eyes with pre-existing episcleral bands. Ophthalmology. 1998;105:2237–2242.PubMedCrossRefGoogle Scholar
  171. 171.
    Schocket SS. The ‘taco’ tube shunt. In: Chen TC ed. Surgical Techniques in Ophthalmology: Glaucoma Surgery. Philadelphia: Saunders Elsevier; 2008:143–152.Google Scholar
  172. 172.
    Roth SM, Brown GC. The diagnosis and management of rubeosis iridis. Clin Signs Ophthalmol. 1989;10:1–15.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Charlotte Eye Ear Nose & Throat AssociatesCharlotteUSA

Personalised recommendations